Impact of Minimally Invasive Surfactant Therapy in Preterm Infants at 29-32 Weeks Gestation.

CONCLUSIONS: Selective use of minimally invasive surfactant therapy at 29-32 weeks gestation permits a primary CPAP strategy to be pursued with a high rate of success, and a low risk of pneumothorax. PMID: 28922658 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28922658?dopt=Abstract

Source: Neonatology - September 19, 2017 Category: Perinatology & Neonatology Authors: Dargaville PA, Ali SKM, Jackson HD, Williams C, De Paoli AG Tags: Neonatology Source Type: research

More News: Bronchopulmonary Dysplasia | Perinatology & Neonatology | Pneumothorax | Respiratory Medicine